Subsequent Pregnancy Outcomes in Patients With Peripartum Cardiomyopathy

Codsi, Elisabeth; Rose, Carl H.; Blauwet, Lori A.

doi:10.1097/aog.0000000000002439

Cited by 43 publications

(25 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 48 A characteristic of preeclampsia and peripartum cardiomyopathy is the recurrence rate, which follows a similar pattern in subsequent pregnancies. Early pre-eclampsia is considered to be the more severe phenotype, with a 34% risk of recurrence, 98 and in patients with PPCM these figures are 15–50%. 81 , 99 Despite the full recovery of some women, there is concern about the risk of recurrence of the condition during a subsequent pregnancy.…”

Section: Methodsmentioning

confidence: 99%

The Relationship Between Peripartum Cardiomyopathy and Preeclampsia – Pathogenesis, Diagnosis and Management

Kuć¹,

Kubik-Machura²,

Kościelecka³

et al. 2022

JMDH

View full text Add to dashboard Cite

Peripartum cardiomyopathy (PPCM) is a condition with an incompletely understood etiology, although many risk factors for this disorder have been mentioned. Preeclampsia (PE) is a rare but undoubtedly very important cause of PPCM. Early recognition and prompt treatment of preeclampsia and peripartum cardiomyopathy are essential to optimize pregnancy outcomes. An extensive manual search of major electronic databases was conducted in November 2021. The following literature review provides a comprehensive discussion of peripartum cardiomyopathy and preeclampsia and quantifies the prevalence of PE in women with PPCM. The authors highlighted aspects such as epidemiology, risk factors, cardiovascular changes, diagnosis and clinical presentation, and management and complications. Accumulating data indicate that both conditions have a similar pathogenesis characterized by vascular abnormalities. In both conditions we can observe an increase in interleukin-6 and gamma interferon, CCL2/MCP1, and decreased SOD activity. sFLT1 (a soluble form of fms-like tyrosine kinase 1), a substance with antiangiogenic and probably cardiotoxic effects, may be important. Preeclampsia and peripartum cardiomyopathy are characterized by recurrence rates that follow a similar pattern in subsequent pregnancies, and mortality remains a concern. Our analysis highlights the need to better understand the co-morbidity of PE and PPCM, and the need to qualify patients for the same clinical trials because of the common origin of these conditions.

show abstract

Section: Methodsmentioning

confidence: 99%

The Relationship Between Peripartum Cardiomyopathy and Preeclampsia – Pathogenesis, Diagnosis and Management

Kuć¹,

Kubik-Machura²,

Kościelecka³

et al. 2022

JMDH

View full text Add to dashboard Cite

show abstract

“…Ninguna de las pacientes que tuvieron una reducción de la FEVI alcanzo el mismo nivel de disminución que se observó en su embarazo índice. En este estudio, no se observaron muertes maternas y todas las pacientes recuperaron función sistólica en el seguimiento post parto 37 . Un dato interesante es el estudio realizado por Gayazzi et al en donde se evidencio que pacientes con miocardiopatía dilatada tenían diferentes resultados pese a tener similar FEVI, sugiriendo que ecocardiografía 2D no es suficiente para evaluar pronóstico por si sola 38 .…”

Section: Riesgo En Embarazo Futurounclassified

“…Se puede considerar el uso de beta bloqueadores (BB) durante embarazos posteriores en mujeres con FEVI recuperada. En el estudio de Codsi et al, 19 de 43 mujeres fueron tratadas con BB sin evidencia de restricción del crecimiento fetal 37 . Se recomienda además realizar seguimiento con ecocardiograma y BNP al final del primer trimestre, final de segundo trimestre, un mes antes de fecha probable de parto, antes del alta y 1 mes posterior al parto.…”

Section: Riesgo En Embarazo Futurounclassified

Miocardiopatía periparto: revisión de la literatura

Martínez

González

2022

Rev Chil Cardiol

View full text Add to dashboard Cite

show abstract

“…(Abou Moulig et al, 2018) Maternal and fetal outcomes are generally positive during future pregnancies. (Codsi et al, 2018) That said, about one-third of women who have had peripartum cardiomyopathy experience relapse in subsequent pregnancies. (Elkayam, 2014) At two years postpartum, maternal mortality ranges from 0% to 9%, with higher rates seen in women of African descent.…”

Section: Cvdsmentioning

confidence: 99%

CE: Gestational Hypertension, Preeclampsia, and Peripartum Cardiomyopathy: A Clinical Review

Maheu‐Cadotte¹,

Pépin²,

Lavallée³

et al. 2019

AJN, American Journal of Nursing

View full text Add to dashboard Cite

Gestational hypertension, preeclampsia, and peripartum cardiomyopathy are among the most common and often severe pregnancy-specific cardiovascular diseases (CVDs) and causes of complications in pregnancy. This clinical review provides nurses with an overview of pregnancyspecific CVDs, outlines their pathophysiology, and discusses risk factors and assessment. It describes management interventions according to timing: the antepartum, intrapartum, and postpartum phases are each addressed.

show abstract

Subsequent Pregnancy Outcomes in Patients With Peripartum Cardiomyopathy

Abstract: Patients with a history of peripartum cardiomyopathy who recover LV function are at risk for a transient minor decrease in LV ejection fraction during future pregnancies, but obstetric and neonatal outcomes are often favorable.

Cited by 43 publications

References 25 publications

The Relationship Between Peripartum Cardiomyopathy and Preeclampsia – Pathogenesis, Diagnosis and Management

The Relationship Between Peripartum Cardiomyopathy and Preeclampsia – Pathogenesis, Diagnosis and Management

Miocardiopatía periparto: revisión de la literatura

CE: Gestational Hypertension, Preeclampsia, and Peripartum Cardiomyopathy: A Clinical Review

Contact Info

Product

Resources

About